Ovoca Bio Regulatory News (OVB)

Ovoca Bio plc

("Ovoca" or the "Company")

Directorate Change

Ovoca Bio plc (LSE: OVB; ISE: OVXA) announces that Nikolay Myasoyedov, a Non-Executive Director of the Company, has notified the board of his intention to step down from the board of Ovoca with immediate effect for personal reasons. Mr. Myasoyedov will remain a director of IVIX LLC ("IVIX"), a subsidiary of Ovoca, and will continue to provide his expertise on the development of its investigational drug, Libicore (BP-101).

Kirill Golovanov, CEO of Ovoca, commented: "On behalf of the Company, I would like to thank Nikolay for his contribution to the board of Ovoca since the acquisition of IVIX last year. We are pleased that Nikolay will continue to serve as a director of IVIX, where his extensive scientific experience and knowledge will be a valuable resource as we progress with the development programme for Libicore."

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: +353 1 679 6363

About IVIX:

IVIX, a Russian‐incorporated company, was formed in 2012 and since that time has sought to develop and subsequently commercialize a proprietary drug candidate, BP-101 (known as "Libicore"), for the treatment of female sexual dysfunction. Libicore is a novel synthetic peptide, administered through a nasal spray. Clinical studies completed to-date have demonstrated statistically significant efficacy in the treatment of a major form of female sexual dysfunction. So far, IVIX has reached and completed Phase III clinical studies in Russia for Libicore. It now intends to seek approval for the marketing of Libicore in the Russian market, as well seek to expand its use internationally.